Tocagen Inc (NASDAQ:TOCA) has earned a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company.
Analysts have set a 12 month consensus target price of $23.67 for the company and are forecasting that the company will post ($0.52) EPS for the current quarter, according to Zacks. Zacks has also given Tocagen an industry rank of 123 out of 265 based on the ratings given to related companies.
Several research analysts recently issued reports on TOCA shares. Stifel Nicolaus started coverage on Tocagen in a research report on Monday, May 8th. They set a “buy” rating and a $24.00 target price on the stock. Evercore ISI reaffirmed an “outperform” rating and set a $28.00 target price on shares of Tocagen in a research report on Tuesday, May 9th. Finally, Leerink Swann started coverage on Tocagen in a research report on Monday, May 8th. They set a “market perform” rating and a $19.00 target price on the stock.
Shares of Tocagen (NASDAQ:TOCA) traded up 4.94% during trading on Friday, reaching $10.83. The company’s stock had a trading volume of 137,575 shares. The company has a 50-day moving average price of $13.16 and a 200-day moving average price of $14.19. Tocagen has a one year low of $9.68 and a one year high of $17.95. The stock’s market cap is $214.51 million.
Tocagen (NASDAQ:TOCA) last announced its earnings results on Tuesday, May 23rd. The company reported ($4.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.70) by $1.41. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. On average, equities research analysts forecast that Tocagen will post ($2.79) earnings per share for the current fiscal year.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Tocagen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tocagen Inc and related companies.